
Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...





